Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in West Virginia: - United Hospital Center — Bridgeport, West Virginia
- WVUH-Berkely Medical Center — Martinsburg, West Virginia
- West Virginia University Healthcare — Morgantown, West Virginia
- Camden Clark Medical Center — Parkersburg, West Virginia
- Princeton Community Hospital — Princeton, West Virginia
Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in West Virginia: - United Hospital Center — Bridgeport, West Virginia
- WVUH-Berkely Medical Center — Martinsburg, West Virginia
- West Virginia University Healthcare — Morgantown, West Virginia
- Camden Clark Medical Center — Parkersburg, West Virginia
- Princeton Community Hospital — Princeton, West Virginia
Phase 3 Recruiting NIH
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 nega…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06058377
Sites in West Virginia: - Vandalia Health/CAMC Institute for Academic Medicine — Charleston, West Virginia
- West Virginia University Healthcare — Morgantown, West Virginia
Phase 3 Recruiting Industry
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…
Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in West Virginia: - West Virginia University Hospital — Morgantown, West Virginia
Phase 3 Recruiting Industry
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed def…
Sponsor: AstraZeneca
NCT ID: NCT05774951
Sites in West Virginia: - Research Site — Charleston, West Virginia
- Research Site — Morgantown, West Virginia
Phase 3 Recruiting Industry
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+,…
Sponsor: AstraZeneca
NCT ID: NCT06380751
Sites in West Virginia: - Research Site — Morgantown, West Virginia
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in West Virginia: - Vandalia Health/CAMC Institute for Academic Medicine — Charleston, West Virginia
- Edwards Comprehensive Cancer Center — Huntington, West Virginia
- West Virginia University Healthcare — Morgantown, West Virginia
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in West Virginia: - West Virginia University Health Sciences Campus — Morgantown, West Virginia
Phase 2 Recruiting Academic/Other
The goal of this project is to evaluate the therapeutic potential of pioglitazone (PIO) to target underlying mechanisms that promote muscle fatigue in patients with breast cancer. This represents an off-label use of this compound, both in …
Sponsor: West Virginia University
NCT ID: NCT05013255
Sites in West Virginia: - West Virginia University Cancer Institute — Morgantown, West Virginia
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in West Virginia: - Massive Bio SYNERGY-AI site — Morgantown, West Virginia
NA Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of ctDNA-guided initiation of CDK4/6 inhibitor therapy using the Signatera™ Designed on Genome test (referred to as "Signatera Genome") in participants with intermediate-risk…
Sponsor: Natera, Inc.
NCT ID: NCT07214532
Sites in West Virginia: - West Virginia University — Morgantown, West Virginia
Phase 4 Recruiting Industry
This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal Growth Factor…
Sponsor: AstraZeneca
NCT ID: NCT07357597
Sites in West Virginia: - Research Site — Charleston, West Virginia
- Research Site — Morgantown, West Virginia